With the Gates Foundation and Johnson and Johnson Ventures, how does baby probiotic Evivo affect the first 1,000 days of life?

Babies born in contemporary society do not have the same gut microbiome as babies born a hundred years ago, and compared to 100 years ago, the advantages of the modern infant gut beneficial bacteria infant Bifidobacteria
B. infantis experienced significant intergenerational losses and a significant increase in the pH of infant waste.from this trivial discovery,
Evolve Biosystems wants to build a healthy gut microbiome for babies across the United States, and has reaped the same positives from venture capital investors such as the Gates Foundation and Johnson and Johnson Innovations. What is the impact of Evolve Biosystems in the first 1,000 days of life?READ MORE:study finds that in the past
90 years, the pH of baby droppings has risen from 5.0 in 1926 to more than 6.0 today, and Evolve Biosystems sees opportunity in it.does B. infantis mean
babies and what health problems does the lack of? Why are there significant intergenerational losses today?EvolveBio introduces Evivo Baby Probiotics, which help babies build a healthy gut microbiome.from mom groups to professionals,
IveBio hopes Eveo will benefit more people.1 From a seemingly trivial scientific discovery Today, many parents consciously supplement their children with probiotics to help them grow up healthy, the most important of which is Bifidobacteria. Bifidobacteria can effectively protect infants from disease, thrive in the baby's intestines within
3-4 days of birth, inhibit the growth of other bacteria, become an advantageous bacterium, but also help to establish a stable microbial microbiome in the baby's intestines, out of the unstable period.A scientific study published in
march this year showed that the pH of baby faeces has risen from 5.0 in 1926 to more than 6.0 today over the past 90 years, a change that may be largely due to the loss of B. infantile B. infantis in the baby intestine and the effects of an increase in potentially harmful bacteria, a phenomenon that has long been overlooked.This seemingly bland discovery has the potential to be a disruptive discovery in pediatric medicine, and
Evolve Biosystems has taken on the great mission of helping babies across the country build a healthy gut microbiome, starting with children to help restore health to America's unbalanced gut environment.doesmean for B. infantis,
2 baby B. infantis?B. infantis is a probiotic that is present in the intestines and is most commonly found in breastfed infants, but becomes less and less common as we age, a group that once dominated the intestines of babies born in developed countries and now dominates in infants in developing countries.Infant Bifidobacteria inhibits the growth of harmful microorganisms in the intestines, helps infants digest lactose from breast milk, reduces intestinal permeability, improves intestinal barriers and resistance, and reduces the incidence of intestinal inflammation, so infants in these areas are less likely to develop allergies and autoimmune diseases than infants and young children in developed countries.Lack of Bifidobacteria in infants can also cause more health problems, from general allergies and eczema to increased incidence of severe type
1 diabetes and obesity; The equilibrium of the microbiome in infrasfest will affect later growth and development in children, and children with lower levels of Bifidobacteria are six times more likely to develop type 1 diabetes, and are more likely to have abnormal weight levels.Photo Source: Evolve Biosystems websiteCompared to a hundred years ago, babies born in contemporary American society have significant intergenerational losses and significantly higher pH in infant faeces than in the gut of beneficial babies
B. infantis. This is largely due to the modern medicine and eating habits applied in industrialized countries, including three main reasons: more pregnant women choose caesarean section: baby Bifidobacteria is transferred to the baby by mother through feces
/mouth during natural childbirth, while babies born by caesarean section do not have access to sufficient baby Bifidobacteria, from 1970 onwards, the proportion of Americans choosing caesarean section increased from 1/20 to 1/3; More mothers choose formula to feed their babies: breast milk contains the characteristic carbohydrate
- breast milk lysobacterium (probiotics), can provide ample food for infants in the intestines and help them grow and reproduce, infants Bifidobacteria will be able to convert breast milk polysaccharides into short-chain fatty acids, effectively reducing the pH of baby faeces to hundreds of years ago levels, so infants have a unique symbica relationship with breast-milk polysaccharides, The link between Bifidobacteria in infants and low polysaccharides in breast milk is significant, and this natural mix has served the natural microbiome in babies, but it is becoming increasingly rare in babies born today. As a result, formula-fed infants are less likely to have large amounts of Bifidobacteria in their bodies, and only 50 percent of babies in the United States are now able to breastfeed up to six months of age; uses antibiotics more frequently: even babies born and breastfed naturally have low or almost non-existent levels of Bifidobacteria, possibly because their mothers have undergone multiple antibiotic treatments that kill Bifidobacteria in the mother's body and cause the mother to have no babies at all during childbirth. Photo Source: Evolve Biosystems website 3 EvolveBio launches Evevo Infant Probiotics which can help babies build a healthy gut microbiome Evolve Biosystems Board Chairman and Lead Scientist Dr. David Kyle points out that the use of formula feeding, caesarean section and antibiotics can lead to "generational loss" of B. infantile bifidobacteria. And Evivo, a probiotic product from the University of California,
Evolve Biosystems, can help babies grow Bifidobacteria and build a healthy gut microbiome, and Evivo is currently the first and only clinically proven probiotic product for infants.
Evivo probiotic combination, pictured: Evolve Biosystems website This probiotic product kit contains bagged active probiotics, mixed bowls and feeding droppers, feeding a bag of babies daily and using them within a month. Powdered live bacteria are stored in cold storage bags and transported in cold chains, and during the critical first few weeks of life, breastfeeding mothers can mix live bacteria with breast milk and feed the baby through a dropper, helping the baby fight harmful bacteria and build a beneficial microbial advantage. Once the kit is ready, you can also purchase a separate supplement that continues to help your baby build a healthy gut microbiome. Photo Source: EvolveBiosystems official website If the newborn is born within
3 months of Evivo live bacteria feeding, there will be an 80% chance that the successful colonization of the infant Bifidobacteria colony will be achieved. In addition, EveBio has launched a MCT oil bacteria suspension product, which can be delivered to the human body through a nasal feeding tube and can be fed by health professionals to babies who cannot return home immediately after being born in a hospital. A recent clinical trial showed that breast-feeding, supplemented by
Evolve's live infant Bifidobacteria products, increased the total number of Bifidobacteria in infants by 79%, and after 30 days of continuous replenishment, harmful bacteria such as E. coli and Bacillus Difficile spores in infants were reduced by 80%, and endotoxins associated with type 1 diabetes, allergies, specificity and genetic allergy dermatitis were significantly reduced. In addition, an increase in short-chain fatty acids in the intestines after supplementation with Bifidobacteria helps reduce the risk of obesity, while helping to reduce the pH of infant intestinal feces to the levels of infants a hundred years ago. Photo Source: Kyle says EvolveBio is developing a simple diagnostic test that allows nutrition experts to quickly determine pH levels in infant feces. With Evivo supplementation of infants with Bifidobacteria, the carrying rate of antibiotic resistance genes in infants decreased by 90%, and the disappearance of antibiotic resistance genes was beneficial to infants and young children. Babies born today have an imbalance in their bodies, carrying antibiotic-resistant genes 10 times higher. 4 From moms to professionals EvolveBio wants Evevo to benefit more people more than
,000 babies have eaten Evivo's live baby Bifido products, and Evivo began selling them on Evivo's website, Jet.com and Amazon a year ago, winning praise from customers. While many mothers say
Evivo helps their children achieve a variety of direct benefits, such as reducing the incidence of infant hernia and eczema, maintaining good sleep, and infants developing less but better quality feces, Evebio modestly points out that Eveo is not a treatment for these symptoms and that these evaluations are not directly supported by clinical data. In the long run, EvolveBio can't prove that babies breastfed with Evivo won't develop diseases like asthma, diabetes or obesity in the future, and EvolveBio has made no commitment to reducing the risk of the disease, after all, no one can predict what will happen to children in 10-15 years. According to a
2016 study by cell Vatanen in Cell, by monitoring the gut microbiome of 222 babies in northern Europe from birth to age 3, a link between low and middle levels of Bifidobacteria in infants and early-oncil autoimmune diseases can be established, with infants in Finland and Estonia having a higher risk of developing autoimmune diseases than infants in Russia, where levels of Bifidobacteria are significantly higher than in the other two countries. EvolveBio takes to social media to target the mother population, and hopes that healthcare professionals, such as neononatrics and pediatricians, will also be able to see the results of the scientific clinical trials that will take place after Evivo and truly trust Evivo's effectiveness to better spread the importance of Bifidobacteria in infants and young children.
,
announced a collaboration with King's College London to study the effects of Evelo's combination with breastfeeding to help 70 babies born by caesarean section recover their baby Bifidobacteria. In addition,
EvolveBio has attracted the attention of many investors, and this year EveBio has made a $40 million round of C financing, led by the Gates Foundation, Horizonsventures, Li Ka Shing Foundation's venture capital division, which includes the new Johnson and Johnson innovation unit JJDC Arla Foods, ContinentalGrain Company, and early investors Tate and Lyle Ventures, Alta Ventures, MLS Capital, Acre Ventures and Bow Capital, while EvolveBio will further expand its collaboration with the Gates Foundation to explore how Evevo can help babies with severe acute malnutrition recover by restoring the gut microbiome.